Pascale, Alina <br/><br/>
Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?  [electronic resource] 

 -  Journal of hepatology  Feb 2013 
 - 391-4 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2012.09.023  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--administration & dosage<br/>Cost-Benefit Analysis<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepacivirus--enzymology<br/>Hepatitis C--drug therapy<br/>Humans<br/>Interferon-alpha--administration & dosage<br/>Oligopeptides--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Proline--administration & dosage<br/>Protease Inhibitors--administration & dosage<br/>Recombinant Proteins--administration & dosage<br/>Ribavirin--administration & dosage<br/>Treatment Outcome